Fibricor is a drug owned by Athena Bioscience Llc. It is protected by 4 US drug patents filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 20, 2027. Details of Fibricor's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7569612 | Methods of use of fenofibric acid |
Aug, 2027
(2 years from now) | Active |
| US7741373 | Methods of use of fenofibric acid |
Aug, 2027
(2 years from now) | Active |
| US7741374 | Methods of use of fenofibric acid |
Aug, 2027
(2 years from now) | Active |
| US7915247 | Methods of use of fenofibric acid |
Aug, 2027
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fibricor's patents.
Latest Legal Activities on Fibricor's Patents
Given below is the list of recent legal activities going on the following patents of Fibricor.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Apr, 2022 | US7741373 |
| 11.5 yr surcharge- late pmt w/in 6 mo, Large Entity | 05 Apr, 2022 | US7741374 |
| Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical | 05 Apr, 2022 | US7569612 |
| Surcharge, Petition to Accept Pymt After Exp, Unintentional. | 05 Apr, 2022 | US7569612 |
| 11.5 yr surcharge- late pmt w/in 6 mo, Large Entity | 05 Apr, 2022 | US7741373 |
| Petition to Accept Late Payment of Maintenance Fee Payment Filed Critical | 05 Apr, 2022 | US7569612 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 05 Apr, 2022 | US7569612 |
| Mail-Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical | 05 Apr, 2022 | US7569612 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 05 Apr, 2022 | US7569612 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Apr, 2022 | US7741374 |
US patents provide insights into the exclusivity only within the United States, but Fibricor is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fibricor's family patents as well as insights into ongoing legal events on those patents.
Fibricor's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Fibricor's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 20, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Fibricor Generics:
There are no approved generic versions for Fibricor as of now.
About Fibricor
Fibricor is a drug owned by Athena Bioscience Llc. It is used for managing elevated cholesterol levels and hyperlipidemias in patients through adjunctive therapy alongside diet. Fibricor uses Fenofibric Acid as an active ingredient. Fibricor was launched by Athena in 2009.
Approval Date:
Fibricor was approved by FDA for market use on 14 August, 2009.
Active Ingredient:
Fibricor uses Fenofibric Acid as the active ingredient. Check out other Drugs and Companies using Fenofibric Acid ingredient
Treatment:
Fibricor is used for managing elevated cholesterol levels and hyperlipidemias in patients through adjunctive therapy alongside diet.
Dosage:
Fibricor is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 35MG | TABLET | Discontinued | ORAL |
| 105MG | TABLET | Discontinued | ORAL |